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Abstract 
Insulin resistance is a defining feature of metabolic syndrome and type 2 diabetes but also may 
occur independently. Nonalcoholic fatty liver disease (NAFLD), the hepatic manifestation of 
these disorders, increases risk of hepatocellular carcinoma (HCC). However, mechanisms linking 
hyperinsulinemia to NAFLD and HCC require clarification. Here, we describe a novel mouse 
model of primary insulin resistance and HCC with strong parent-of-origin effects. Male AB6F1 
(A/JCr dam x C57BL/6 sire) but not B6AF1 (B6 dam x A/J sire) mice developed spontaneous 
insulin resistance, NAFLD and HCC without obesity or diabetes. A survey of mitochondrial, 
imprinted, and sex-linked traits revealed modest associations with X-linked genes. However, a 
diet-induced obesity study including B6.A chromosome substitution-strain (consomic) mice 
showed no segregation by sex chromosome. Thus, parent-of-origin effects were specified within 
the somatic genome. Next, we interrogated mechanisms of insulin-associated 
hepatocarcinogenesis. Steatotic hepatocytes exhibited adipogenic transition characterized by 
vacuolar metaplasia and upregulatation of vimentin, adipsin, fatty acid translocase (CD36), 
perosixome proliferator-activated receptor-γ, and related genes. This profile was largely 
recapitulated in insulin-supplemented primary mouse hepatocyte cultures. Importantly, pyruvate 
kinase M2, a fetal anabolic enzyme implicated in the Warburg Effect, was activated by insulin in 
vivo and in vitro. In summary, our study reveals parent-of-origin effects in heritable insulin 
resistance, and implicates adipogenic transition with acquired anabolic metabolism in the 
progression from NAFLD to HCC. 
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Introduction 
Metabolic diseases such as obesity, insulin resistance, metabolic syndrome and type 2 diabetes 
(T2D) are reaching epidemic proportions.1 Serious co-morbidities are associated with these 
conditions including hypertension, cardiovascular disease and increased risk for several types of 
cancer.2, 3 Nonalcoholic fatty liver disease (NAFLD), the hepatic manifestation of this group of 
disorders, increases the risk of hepatocellular carcinoma (HCC).4 HCC is the 3rd leading cause of 
cancer deaths worldwide, and the fastest rising cancer in the United States.5 In a recent 
prospective study of asymptomatic U.S. middle-aged adults, the prevalence of NAFLD by 
ultrasound and/or biopsy was found to be 46%.6 Nonalcoholic steatohepatitis (NASH), the more 
serious NAFLD subcategory defined by hepatic steatosis, inflammation and ballooning 
degeneration, afflicts 12% of middle-aged Americans.6 As a result, NAFLD/NASH may one day 
surpass hepatitis C virus infection as the leading cause of HCC in this country.  
 
Genetic predisposition contributes to HCC risk on a metabolic background, but molecular 
markers of preneoplastic progression and hepatocellular transformation remain elusive. 
Moreover, due to extensive overlap in clinical presentation, it is difficult to ascribe hepatic 
consequences such as NAFLD and HCC to specific metabolic triggers. Existing animal models 
of metabolic hepatopathy are ill-equipped to address these questions because most exhibit 
obesity, insulin resistance and/or T2D as part of a disease continuum. New models are needed to 
dissect the roles of individual metabolic parameters in the pathogenesis of hepatic steatosis and 
carcinogenesis. Here, we report a novel mouse model of primary insulin resistance and NAFLD 
leading to HCC in the absence of obesity or T2D. Intriguingly, the model exhibits strong parent-
of-origin effects encoded predominantly within the somatic genome, suggesting involvement of 
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imprinted genetic elements that may serve as useful biomarkers and/or interventional targets. We 
used this model to probe mechanisms of hyperinsulinemic NAFLD and HCC, and documented 
adipogenic transition of hepatocytes with reactivation of the anabolic enzyme pyruvate kinase 
M2, a fetal proto-oncogene associated with the Warburg Effect.7 Taken together, our results 
suggest that epistatic interactions between parent-specific loci play an important role in 
regulating insulin sensitivity, and that hepatocellular adipogenic transition with acquired 
anabolic metabolism represents a potential mechanistic link between NAFLD and HCC. 
 
Materials and Methods 
 
Animals and Study Design 
 
A/JCr mice (A/J) were purchased from the National Cancer Institute (Frederick, MD). C57BL/6J 
(B6) and B6.A chromosome substitution-strain (CSS; consomic) mice were obtained from the 
Jackson Laboratory (Bar Harbor, ME). Experiments were performed in facilities accredited by 
the Association for Assessment and Accreditation of Laboratory Animal Care. Mice were 
maintained in static microisolator cages under specific pathogen-free conditions for 11 murine 
viruses, Helicobacter spp., Salmonella spp., Citrobacter rodentium, ectoparasites and 
endoparasites. Helicobacter-free status was confirmed by DNA PCR on pooled cage feces.8 In 
the first experiment, A/J and B6 mice were intercrossed and parent-of-origin records maintained 
to identify offspring as AB6F1 or B6AF1. All F1 offspring (n=59) were fed the same rodent 
chow diet (Prolab RMH 3000; Scott’s Distributing, Hudson, NH)  and collected at 3, 9 or 15 
months of age. In a follow-up diet-induced obesity (DIO) study, A/J, C57BL/6J-Chr XA/J/NaJ 
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(B6.AX), C57BL/6J-Chr YA/J/NaJ (B6.AY), AB6F1 and B6AF1 mice were raised under 
standard conditions until 6 weeks of age and then randomly assigned into low-fat (LF) or high-
fat (HF) diet groups (minimum 8 animals per sex per group, n=207). The LF diet contained 10 
kcal%fat and the HF diet 60 kcal%fat (catalog numbers D12450B and D12492; Research Diets, 
New Brunswick, NJ). Mice were maintained on the LF or HF diet for 12 weeks. Mice in both 
studies were euthanatized via CO2 inhalation according to recommendations of the AVMA Panel 
on Euthanasia. Protocols were compliant with the U.S. Public Health Service Policy on Humane 
Care and Use of Laboratory Animals, and approved by the Massachusetts Institute of 
Technology Committee on Animal Care and University of North Carolina Institutional Animal 
Care and Use Committee. Body weight was recorded and blood collected via cardiac puncture 
immediately following euthanasia. Full necropsies were performed and blood and tissues 
collected per our published protocol.9 
 
Blood and tissue analyses 
 
Blood glucose concentrations were obtained using the One Touch Basic glucometer (LifeScan, 
Milpitas, CA). Cholesterol was measured with the Accutrend GC (Roche Diagnostics, 
Branchburg, NJ). Serum insulin was determined with the Lincoplex rat/mouse insulin ELISA kit 
(Millipore, Billerica, MA). The homeostatic model of assessment for insulin resistance (HOMA-
IR) was calculated as described.10 Parametric laboratory data between all groups were compared 
by one-way analysis of variance (ANOVA) with Tukey post-test, and between pairs by Student 
t-test using Prism software (GraphPad, San Diego, CA). P-values < 0.05 were considered 
significant. Hematoxylin and eosin-stained slides of liver were graded by a board-certified 
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veterinary pathologist (A.B.R.) blinded to sample identity for hepatic steatosis based on semi-
quantitative percentage of centrilobular and midzonal hepatocytes containing lipid vacuoles: (0) 
< 5% of hepatocytes, (1) 5-25%, (2) 25-50%, (3) 50-75%, (4) >75%. Macrovesicular and 
microvesicular steatosis were scored separately according to published morphologic criteria. The 
combined scores were added to generate a fatty liver index. Inflammation and 
dysplasia/neoplasia also were scored according to our published criteria.9 Nonparametric 
histopathology scores were compared between all groups by Kruskal-Wallis ANOVA with 
Dunn’s post-test, and between pairs by Mann Whitney-U. Frozen liver sections in O.C.T. 
medium were cryosectioned and stained with oil red O for lipids. Immunohistochemistry for 
PKM2 (antibody #3198, Cell Signaling Technology, Beverly, MA) was performed on a Bond-III 
immunostainer (Leica, Bannockburn, IL) following techniques we have published.11 
 
Gene expression analysis 
 
mRNA was isolated from liver and assessed for quality as we have previously described.12 
Tissues from two 9-month-old male AB6F1 and B6AF1 mice were analyzed using the Mouse 
Genome 430A 2.0 Array (Affymetrix, Santa Clara, CA). Data were imported into Partek 
Genomics Suite (Partek, St. Louis, MO) using Robust Multichip Average, and normalized by 
response variable. Data were filtered by presence/absence call and P-value (<0.05). Signal fold-
changes ≥1.5 were considered significant. The complete data set was deposited in the NIH Gene 
Expression Omnibus, #GSE26225. Results for selected genes were validated and extended 
across all groups by SYBR green quantitative RT-PCR (qRT-PCR) as described previously.13 
Primers were designed using MacVector 11 software (Cary, NC). Unique primer sequences are 
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presented in Table 1; all others as described by Amador-Noguez et al.14  
 
Primary hepatocyte isolation and culture 
 
Primary mouse hepatocytes were derived from collagenase-digested 8-week-old male B6 mouse 
livers, and isolated and cultured following protocols described elsewhere with minor 
modification.15 Briefly, murine livers were sequentially perfused in situ with 25 mL calcium-free 
EGTA-containing buffer followed by 50 mL buffered saline containing 0.3 mg/mL Type IV 
collagenase (Roche Diagnostics Corp, Indianapolis, IN) at 37o C. Following perfusion, 
collagenase-treated livers were dissociated by mincing with scissors followed by passage 
through a 100 µm-pore nylon mesh. Hepatocytes were purified via repeated (3X) low-speed (50 
x g) centrifugation. Cell purity was assessed by light microscopy and by fluorescence-assisted 
cell sorting. For the latter, 1x105 cells were labeled with anti-CD45/leukocyte-common antigen 
or anti-Fas (CD95) antibodies (or appropriate conjugated isotype control antibodies, all from 
eBioscience, San Diego, CA) for 30 minutes at room temperature followed by evaluation on an 
Accuri C6 Flow Cytometer (Ann Arbor, MI). Purified hepatocytes were grown on collagen I-
coated matrices (BD Biocoat, BD Biosciences, Franklin Lakes, NJ) in Dulbecco’s modified 
Eagle medium with 10% fetal bovine serum, penicillin/streptomycin, and 2 mM L-glutamine. 
Subsets of cells were supplemented with insulin (5 mg/L), transferrin and selenium (ITS) ± 
dexamethasone (10 mM; both Sigma, St. Louis, MO). After 1 or 4 days, cells were harvested and 
RNA isolated followed by qRT-PCR as described above. Cell viability was determined using a 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) kit according to the 
manufacturer’s instructions (Molecular Probes, Eugene, OR). For assessment of hepatocyte 
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morphology, cell suspensions were dropped onto silanized glass slides, fixed in chilled acetone 
for 10 min, and stained with Diff-Quik (Fisher Scientific, Pittsburgh, PA).  
 
Results 
 
Insulin resistance without obesity or T2D in AB6F1 male mice  
 
We characterized the phenotype of AxB F1 mice fed a standard rodent chow diet for 3, 9 or 15 
months. First, body and liver weights were determined. AB6F1 male mice weighed 15-23% 
more than age-matched B6AF1 controls when compared across time points (Fig. 1). Whereas 
this difference was statistically significant, AB6F1 mice were not obese and could not be 
visually distinguished from BA6F1 males. Female AB6F1 mice also weighed slightly more than 
B6AF1 females, but the difference was statistically insignificant (not shown). AxB F1 mice of 
both sexes weighed more than published mean body weights for either parental inbred strain 
(Mouse Phenome Database, Jackson Laboratory). Thus, hybrid mice were larger than parental 
strains, but morbid obesity was not a component of the F1 phenotype. At necropsy, it was noted 
that the livers of many males were enlarged and pale. Absolute liver weight and liver:body 
weight ratios were found to be greater in AB6F1 than B6AF1 male mice at 9 and 15 months 
(Fig. 1). Male AB6F1 had significantly increased serum insulin levels relative to B6AF1 males at 
all time points. Nevertheless, despite increased serum insulin levels in AB6F1 males there were 
no significant differences in mean blood glucose between any groups regardless of sex or time 
point (not shown). Moreover, no animals developed polyuria, polydipsia, hyperphagia and/or 
body wasting characteristic of diabetes.16 Thus, in spite of high circulating insulin levels, AB6F1 
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mice did not exhibit obesity or T2D. These results demonstrate that AB6F1 but not B6AF1 male 
mice develop spontaneous hyperinsulinemia on a standard chow diet, and that this insulin 
resistance is not associated with morbid obesity, metabolic syndrome or T2D. 
 
Hyperinsulinemic NAFLD and HCC in AB6F1 males 
 
Blinded histopathologic assessment of livers from AxB F1 mice revealed mild-to-moderate 
hepatic steatosis in a subset of animals by 3 months of age, marked steatosis by 9 months, and 
severe steatosis with dysplasia and/or HCC by 15 months. When the results were decoded, it was 
confirmed that the most significant lesions arose in hyperinsulinemic AB6F1 males (Fig. 2A). 
B6AF1 males showed no or minimal liver lesions at 3 and 9 months of age. However, 50% of 
BA6F1 males did exhibit mild-to-moderate steatosis at 15 months. In AB6F1 males, histologic 
changes characteristic of insulin resistance were identified in tissues besides the liver as well. 
These included WAT degeneration with F4/80+ pericellular macrophages forming crown-like 
rosettes, thoracic BAT metaplasia to a WAT phenotype, focal skeletal muscle degeneration with 
fatty replacement, and pancreatic islet hyperplasia with occasional megaislets (Fig. 2B). Within 
the liver, preneoplastic and neoplastic lesions including foci of cellular alteration, dysplastic 
nodules and HCC were limited to AB6F1 males (30% incidence versus 0% in BA6F1; Fig. 2C). 
This is significant because spontaneous HCC is very rare in wild-type (WT) A/J and B6 strains 
within the typical 24-month lifespan (Mouse Phenome Database). Because high insulin levels 
also have been associated with tumors of the pancreas and lower bowel,17, 18 we examined those 
organs grossly and histologically but found no neoplastic or preneoplastic lesions (not shown). 
Histopathology of female mouse tissues including liver was unremarkable. These findings are 
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consistent with the male-predominance of metabolic and neoplastic liver disease documented in 
humans and other rodent models.6, 19 Viewed together these results demonstrate that 
hyperinsulinemia, in the absence of morbid obesity, metabolic syndrome or T2D, is sufficient to 
induce HCC in mice. 
 
NAFLD-associated cytokine induction, acute-phase responses and hepatic feminization 
 
To determine the global impact of hepatic steatosis on gene expression, we performed 
microarray analysis of liver samples from 9-month-old male AB6F1 and B6AF1 mice. 
Hierarchal clustering analysis using Partek Genomics Suite demonstrated clear segregation of the 
two genotypes (Fig. 2D). Four interrelated pathophysiologic processes were evident in the 
steatotic male AB6F1 liver: inflammation, acute-phase responses (APR), transcriptional 
feminization, and metabolic derangement. Numerous proinflammatory genes were upregulated 
including Stat1, IFN-γ-induced GTPases and interferon-activated/regulatory factors, 
histocompatibility 2 class II antigens, and others (top 10 altered genes Table 2; complete data set 
available Gene Expression Omnibus #GSE26225). APR induction was confirmed by the 
upregulation of canonical acute-phase murine genes including lipocalin 2, serum amyloid A1 and 
A2, orosomucoid, and metallothioneins 1 and 2.12 Of note, all of these transcriptional changes 
occurred in the absence of histologic hepatitis, demonstrating that NAFLD produces a 
morphologically covert pro-inflammatory microenvironment. Nonspecific injury of the male 
mouse liver frequently leads to loss of gender-specific gene expression characterized by 
transcriptional feminization.13 Accordingly, we found a significant bias for sex-dependent gene 
alterations in the feminine direction in AB6F1 males with NAFLD. Feminine genes up-regulated 
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in the steatotic male liver included sulfotransferase 2a2 and Sult3a1, cytochrome P450 2b13 
(Cyp2b13), lymphocyte antigen 6 complex locus D, ATP-binding cassette D2, fatty acid-binding 
protein 5 (epidermal), and acyl-CoA thioesterase 3. Simultaneously, masculine genes were 
downregulated in the male AB6F1 liver including solute carrier organic anion transporter 1a1, 
hydroxysteroid dehydrogenase 3β-V, elongation of very long chain fatty acids-like 3, elastase-1 
(pancreatic), and Cyp7b1. Whereas many of the metabolic gene alterations in AB6F1 male mice 
were attributable to hepatic feminization, gender-neutral genes associated with metabolic 
function also were dysregulated including potassium channel T2, complement factor D (adipsin), 
sulfotransferase 5A1, and insulin-like growth factor binding protein 2. Taken together, these data 
demonstrate that insulin resistance and NAFLD are sufficient to invoke robust hepatic 
transcriptional alterations related to inflammation, metabolism and sex-dependent liver function. 
 
Parent-of-origin effects not linked to known maternal/paternal genes 
 
There are three known sources of parent-specific gene expression: mitochondrial DNA, 
imprinted loci, and sex-linked genes.20 Genes transcribed from mitochondrial DNA are maternal 
in origin, imprinted genes are transcribed from a single parental allele, and sex chromosomes are 
inherited in parent-specific fashion in males. Because of the strong parent-of-origin effects in 
AxB F1 mice, we interrogated by qRT-PCR genes meeting any of those criteria and shown to be 
differentially expressed by microarray. Additionally, we analyzed known parent-specific genes 
canonically associated with metabolism. Altogether, we assessed 4 mitochondrial DNA 
transcripts, 8 imprinted alleles, and 29 sex-linked genes in all male mice (Table 1). No imprinted 
or mitochondrially-encoded gene exhibited differential expression between AB6F1 and B6AF1 
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mice (data not shown). In contrast, four X-linked genes showed a positive correlation with 
NAFLD at one or more time points. Of these, three were upregulated at 9 and 15 months only 
(Frmpd3, Slc25a5, Tmsb4x), suggesting an associative rather than causative relationship. The 
only X-linked gene upregulated at all time points in AB6F1 males was thyroxine-binding 
globulin (TBG; Serpina7). Interestingly, this gene also was increased in B6AF1 males with 
steatosis at 15 months. However, in all affected animals TBG upregulation was modest (~2-fold) 
and showed no linear correlation with NAFLD severity (data not shown). Further work will be 
required to determine whether TBG contributes to the pathogenesis of insulin resistance and 
NAFLD or is merely a bystander. Viewed as a whole, our PCR survey failed to identify a robust 
candidate among known uniparentally expressed genes to account for the dramatic parent-
specific metabolic phenotype in AxB F1 males, suggesting that the disease is polyfactorial and 
may involve epigenetic mechanisms.  
 
Gender- and strain-specific responses to high-fat diet in CSS and F1 mice 
 
Because we found some associations between X-linked genes and the AB6F1 metabolic 
phenotype, we performed a follow-up DIO study using sex chromosome-substitution strain B6.A 
mice. These animals were on a B6 background except for an A/J-derived sex chromosome.21 
Also included were AxB F1 mice along with a WT A/J control group. An additional control 
group of WT B6 mice had to be excluded due to poor breeding kinetics resulting in insufficient 
numbers. In agreement with the first study showing increased BW in AxB F1 mice relative to the 
parent strains, B6AF1 and AB6F1 mice on the LF diet weighed significantly more than sex-
matched A/J and CSS strains (Table 3). All mice on the HF diet weighed significantly more than 
 13 
sex- and strain-matched animals on the LF diet. However, as a percentage of baseline body mass, 
CSS mice on the HF diet gained more weight than A/J and F1 mice. This was especially true of 
B6.AX males, which weighed less than all other male groups on the LF diet, but the same as all 
but the A/J males on the HF diet. In A/J and CSS mice, serum insulin levels rose in relative 
proportion to body mass on the HF diet. In stark contrast, insulin levels were significantly lower 
in B6AF1 and significantly higher in AB6F1 males compared with CSS mice despite nearly 
identical body weights (Fig. 3). A similar dichotomy between serum insulin and body mass was 
observed in female F1 mice on the HF diet. Thus, insulin resistance in F1 mice was regulated by 
distinct mechanisms from those governing diet-induced weight gain. Female CSS and AxB F1 
but not A/J mice on the HF diet exhibited mild-to-moderate macrovesicular steatosis that did not 
vary by strain (data not shown). Male A/J mice on the HF diet developed moderate patchy 
macrovesicular steatosis, whereas CSS and F1 males developed severe diffuse mixed hepatic 
steatosis (mean fatty liver index = 5/8; not shown). The proportion of microvesicular-to-
macrovesicular steatosis varied within but not between groups. Viewed as a whole, these results 
demonstrated that weight gain and hepatic steatosis increased in tandem in response to the HF 
diet, whereas insulin resistance was distinctly regulated in F1 male and female mice. Indeed, 
B6AF1 were protected from DIO-associated insulin resistance compared with CSS mice, 
whereas AB6F1 displayed exaggerated hyperinsulinemia in response to caloric overload. This 
suggests synergy in epistatic interactions between parent-specific alleles in hybrid mice resulting 
in a marked shift in insulin sensitivity in a positive or negative direction. Taken together, these 
results show that insulin resistance is not directly correlated with increased body mass, and that 
additional genetic factors determine the metabolic consequences of diet-induced obesity. 
 
 14 
Insulin resistance invoked adipogenic transition of hepatocytes and reactivated PKM2 
 
Because of the remarkable histologic similarity between steatotic hepatocytes and adipocytes 
(Fig. 2E), we wondered whether fatty liver was associated with molecular changes characteristic 
of adipogenic transition.22 By microarray and qRT-PCR, we found numerous examples of 
adipocyte-associated genes that were upregulated in the livers of 9-month-old AB6F1 mice with 
NAFLD compared with B6AF1 controls. As mesenchymal cells, adipocytes express a number of 
canonical genes not typically expressed in hepatocytes and other epithelial tissues. Mesenchymal 
cell markers that were increased in the livers of mice with NAFLD included vimentin, platelet-
derived growth factor-β, and collagen 3α-1 (Fig. 4A and Supplemental Data). Additionally, there 
was upregulation of more specific adipocyte-associated genes including complement factor D 
(adipsin), fatty acid translocase (CD36), fatty acid binding protein-4 (adipocyte), and peroxisome 
proliferator-activated receptor-γ (PPARγ). Of singular importance, the fetal isoform of pyruvate 
kinase, Pkm2 was upregulated nearly 2-fold in 9-month-old mice with NAFLD. Functional 
protein expression was confirmed by IHC, where cytoplasmic and nuclear PKM2 localization 
was visualized in neoplasms from AB6F1 mice, but not in normal B6AF1 liver (Fig. 2A). These 
results confirm that chronic hyperinsulinemia invokes adipogenic transition of hepatocytes and 
invokes metabolic pathways in improper context that may contribute to cellular transformation. 
 
Insulin-dependent adipogenic transition and PKM2 activation in cultured hepatocytes 
 
To validate our in vivo findings and confirm that transcriptional alterations reflected changes in 
parenchymal and not accessory liver cells, we harvested, purified and cultured primary mouse 
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hepatocytes. To insure purity, we performed FACS analysis which confirmed <2% 
contamination by white blood cells (Fig. 4A). Approximately 25% of the purified hepatocytes 
were positively labeled with an anti-CD95/Fas antibody, in keeping with the known low level of 
Fas surface expression in healthy mouse liver.23 To insure that our cultured cell population was 
primarily hepatocytes, we performed qRT-PCR for albumin and Apoa1 on freshly purified cells 
and found gene expression levels similar to those from intact mouse liver RNA (not shown). 
Primary hepatocytes grown in the presence of insulin exhibited greater viability after 4 days than 
did those grown without insulin supplementation (Fig. 4B). Under all growth conditions, primary 
hepatocytes organized into crude canalicular structures; however, insulin-supplemented cells 
exhibited clear cytoplasmic lipid-storage vacuoles that were not evident in cells grown in the 
presence of dexamethasone alone (Fig. 4B). Insulin supplementation to primary hepatocytes 
resulted in upregulation of many of the same adipocyte-associated genes we documented in 
AB6F1 mice with NAFLD, including but not limited to vimentin, collagen 3α-1, fatty acid 
translocase (CD36) and Pkm2 (Fig. 4C). Taken together, these results confirm that 
supraphysiologic levels of insulin promote hepatocyte survival and invoke activation of 
adipocyte-associated metabolic pathways that may contribute to cellular transformation.  
 
Discussion 
 
Beneath the current wave of obesity and T2D lurks a larger swell of subclinical metabolic 
disease. In some settings, up to 75% of individuals with NAFLD are nonobese.24 Most diagnoses 
of NAFLD in the United States are made in patients without previously identified risk factors. 
Indeed, in a recent study, nearly half of clinically healthy middle-aged adults in the U.S. 
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exhibited NAFLD by ultrasound and/or biopsy.6 The potential impact of covert insulin resistance 
and NAFLD on a national scale is unknown. However, it is noteworthy that HCC continues to 
rise in the United States despite flat or declining levels of viral hepatitis and alcoholism. Indeed, 
NAFLD/NASH may one day surpass HCV infection as the leading cause of liver cancer in the 
United States.5 
 
Because of the complex interactions between metabolic disease and HCC, animal models are 
needed to characterize the molecular events leading from steatosis to cancer. We observed that 
male F1 offspring of A/J and B6 mice developed spontaneous insulin resistance, NAFLD and 
HCC without obesity or T2D. Intriguingly, the model exhibited strong parent-of-origin effects. 
AB6F1 but not B6AF1 mice developed early onset insulin resistance and NAFLD that 
progressed to HCC in many by 15 months of age. Despite this parent-of-origin-specific 
inheritance, we found no strong associations with known uniparentally expressed mitochondrial 
or imprinted genes, although modest associations with some X-linked genes were suggested. 
However, a follow-up DIO study involving X and Y CSS mice confirmed no significant 
phenotypic segregation by sex chromosome, although B6.AX mice did exhibit a leaner metabolic 
profile than B6.AY mice on the LF diet. We concluded that the strong parent-of-origin effects in 
AxB F1 mice were specified within the somatic genome. Importantly, the DIO experiment also 
revealed that obesity and insulin resistance were regulated by distinct genetic mechanisms in 
hybrid animals. 
 
Diabetes is associated with increased risk of HCC in humans.25 In diabetic patients, treatment 
with sulphonylurea or exogenous insulin increases HCC risk and worsens tumor response to 
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radioablation, whereas HCC patients taking the insulin-sensitizing drug metformin have more 
favorable outcomes.26-28 This suggests a direct role for insulin in liver tumor promotion. Because 
insulin resistance in the absence of obesity or diabetes was sufficient to promote HCC in AB6F1 
mice, we investigated potential mechanisms of metabolic hepatocarcinogenesis. In mice with 
hyperinsulinemic NAFLD, hepatocytes underwent partial adipogenic transition characterized 
morphologically by vacuolar metaplasia resembling WAT or BAT. At the molecular level, 
canonical adipocyte genes were activated in steatotic hepatocytes including vimentin, adipsin, 
fatty acid translocase (CD36), fatty acid-binding protein 4 (adipocyte), stearoyl-coA desaturase 
2, and PPAR-γ. This transcriptional profile was largely recapitulated in insulin-supplemented, 
but not deprived, primary mouse hepatocytes in vitro. Supraphysiologic insulin exposure also 
promoted hepatocyte survival in culture. Of special significance discussed below, we found that 
excess insulin reactivated the fetal isoform of pyruvate kinase (PKM2) in hepatocytes both in 
vitro and in vivo.  
 
Complex metabolic traits are regulated polygenetically.29 Thus, our inability to pinpoint a single 
gene that accounted for the parent-specific metabolic phenotype in AxB F1 mice was not 
surprising. Because neither parental inbred strain develops equivalent disease, polygenetic 
crosstalk rather than a single gene polymorphism best explains the positive and negative 
heterosis observed in B6AF1 and AB6F1 males, respectively.30 Whereas our genomic survey of 
F1 mice did reveal a modest association between NAFLD and X-linked thyroxine-binding 
globulin, the follow-up DIO study with CSS mice did not validate phenotypic segregation by sex 
chromosome. In the original description of B6.A CSS mice, it was noted that 17 of the 23 CSS 
lines exhibited an intermediate obesity phenotype between parental inbred strains.21 Thus, 
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metabolism is governed by multiple genes on an array of different chromosomes. Recent work 
has revealed important obesity-related quantitative trait loci on chromosomes 6 and 17.31, 32 
Others are likely to follow. Combining our results with those from other laboratories, it seems 
clear that polygenic epistatic interactions including those inherited in a parent-specific fashion 
coordinately regulate insulin sensitivity. These findings take on direct translational significance 
in light of a recent study from Iceland showing that parent-specific somatic polymorphisms 
strongly influence T2D risk in humans.33 
 
In addition to its value as a genetic tool, the AxB mouse model has utility for addressing 
molecular mechanisms of hepatocarcinogenesis in the context of primary insulin resistance. For 
example, we observed that vacuolated hepatocytes in mice with hyperinsulinemic NAFLD not 
only took on a morphologic appearance of WAT or BAT, but also expressed many genes 
classically associated with adipose tissue. These included but were not limited to adipsin, fatty 
acid translocase, fatty acid binding-protein 4, vimentin and PPARγ. The important role of insulin 
in adipogenic transition was confirmed by our in vitro experiments that recapitulated the 
emergence of lipid vacuoles along with up-regulation of adipogenic genes in primary mouse 
hepatocytes. Moreover, we confirmed that insulin extends hepatocyte survival and inhibits 
apoptosis. This may have in vivo significance, as liver cells undergoing severe oxidative stress in 
a pro-inflammatory microenvironment would be prevented from entering apoptosis in the 
context of hypersinulinemia, as shown experimentally in skeletal muscle.34 
 
A singularly important potential link between hyperinsulinemia, adipogenic transition and HCC 
revealed by this study was pyruvate kinase M2. Pyruvate kinases are critical enzymes in 
 19 
glycolytic oxidative phosphorylation. There are four pyruvate kinase isoforms: L, R, M1 and 
M2.35 The adult liver is characterized by expression of the L-type isoform.36 In contrast, M2 is 
expressed predominantly during embryogenesis in the fetal liver and other rapidly dividing 
tissues.37 In contrast to the adult isoforms, PKM2 diverts glucose metabolism to an alternate 
pathway that generates short carbon chains for molecular building blocks needed by rapidly 
dividing cells.38 Aberrant expression of PKM2 is a common feature of cancers that rely on 
aerobic gycolysis with lactate generation (Warburg Effect) to support rapid proliferation. 
Intriguingly, PKM2 is activated normally in an insulin-dependent fashion during the 
programmed differentiation of NIH 3T3 cells from preadipocytes to adipocytes.39 It is possible 
that insulin invokes adipogenic transition and Pkm2 expression in hepatocytes through similar 
mechanisms. Of note, the only two adult mammalian tissues that ordinarily express PKM2 are 
skeletal muscle and adipose tissue, both of which are replicatively senescent.40, 41 In contrast, 
hepatocytes enter cell division with little prompting. It is tempting to speculate that insulin-
directed PKM2 reactivation in replication-competent cells such as hepatocytes represents a 
significant proto-oncogenic event. If so, PKM2 inhibitors currently under development for the 
treatment of established cancer also may have utility for the prevention of HCC in patients with 
insulin resistance and NAFLD.42 Further study will be required to test this hypothesis. 
 
In summary, we have introduced a novel mouse model of primary insulin resistance, NAFLD 
and HCC with strong parent-of-origin effects. AB6F1 but not B6AF1 male mice develop 
spontaneous insulin resistance that leads to severe NAFLD by 9 months and HCC by 15 months. 
Parent-specific inheritance in this model is polygenetic and encoded within the somatic genome. 
We have shown that insulin resistance is regulated independently of diet-induced weight gain in 
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AxB F1 mice, and that hyperinsulinemia is associated with adipogenic transition of hepatocytes. 
Among the adipocyte-associated genes in this program is PKM2, an anabolic enzyme implicated 
in tumorigenesis and the Warburg Effect. Viewed as a whole, our study implicates the existence 
of somatic parent-specific loci that may serve as useful biomarkers for metabolic risk profiling, 
and identifies new potential targets to improve insulin sensitivity and prevent NAFLD-associated 
HCC.  
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Table 1. Primer sequences for qRT-PCR. 
 
Gene Forward (5’-to-3’) Reverse (5’-to-3’) Region 
Mitochondrial   
Cox1 TGGAGGCTTTGGAAACTGACTTG GAGAAGGAGAAATGATGGTGGTAGG 325-436 
Cytb GGTGCCACAGTTATTACAAACCTCC AGCGAAGAATCGGGTCAAGG 524-640 
Nd1 CTTGTTCCCAGAGGTTCAAATCC GGTTGTAAAATGCCGTATGGACC 67-243 
Rnr2 CAAGAACCCCGCCTGTTTACC GTTGGACCCTCGTTTAGCCG 926-1078 
Imprinted    
Ctcf TTTGTCACGCTCGGTTTACCC TGCTGCTTTCGCAAGTGGAC 1500-1647 
Dio3 CAACAGTGAAGGCGAGGAGATG TGGGCTTGCTTGAAGAAATCC 260-391 
Grb10 GGTTTTTCTCCGTTGTGACTCG TTGGCTTCTTTGTTGTGGCG 231-378 
H19 TGTGATGGAGAGGACAGAAGGG CAGAGAGCAGCAGAGAAGTGTTAGC 972-1096 
Igf2 TCGTGTTACCACCCAAAGACCC GATGGAACTGTCCCTGCTCAAG 1701-1842 
Igf2as ATGAAGGGAAGGCTGGCTTG CTGGTTTACAGGTCTGGTTTGAGC 571-699 
Rtl1 AGCGACAGTTCAAACCAGTCAAG CTCGTCATCTCCCAGGTCAGTATC 1042-1188 
Sgce GCAGTCAAGAAATGGAGCCTGTG GCCACGAACTACTTCCTGATAGGTG 765-895 
X-linked    
Arhgap6 TCCACTTTGACTACGAGGTCCCAC AGGAACTGACGATGCTTGCG 594-722 
Atp11c TTGATGGACCTGTAGAAGGAGCC CCCAAAAATGTGAACCCAAACC 1589-1691 
Bgn CGGATGATTGAGAATGGGAGCC CCTTGGTGATGTTGTTGGAGTGC 941-1088 
Bhlhb9 AAAGGGAAAGGTAAGGCAGGC TCCTATGGTTGAAATCTGAGGTGC 266-413 
Cd99l2 GGTCCCAAAAAGCCAAGTGC GGTCATCGTTGCTGCCATAACC 313-442 
Efnb1 AAGTGGCTTGTGGCTATGGTCG GCTTGTCTCCAATCTTCGGGTAG 788-935 
EG245643 TCTCTGCTTGGTTGAACGCAC ATGCCCGAAGAATCAGTCAGG 1153-1293 
Flna TTCTCTGTCTGGTATGTCCCTGAAG TCACTTTGCTGGCATCACCC 1122-1251 
Gpc4 TCCTCCTCCTCCTTCACTACCAAC ACCTTTAGGGGACAGAATGAGACC 315-442 
Gyk CCAAGAGAAGGATGGGTAGAACAAG GCTGACACCAATGGCTTTGATG 458-589 
Ikbkg GCTGGTGGAGAAGAAGGAGTATTTG TGGAGCAGGGAGTAAAGGAGGC 957-1110 
Msn GCGGTCCTGTTGGCTTCTTATG CCTTGTTGAGTTTGTGCTGCTCC 551-683 
Pdzd11 CCTATGAAAACCCTCCAGCGTG AAATCCCAACTGAGCACCAGG 156-286 
Praf2 AGAGCATCGGTCTAAAGCGGAC AAAGGGTTGGTCTTGGGTATGG 475-613 
Prdx4 CCTCTTCTTTCTGACCTGAACCATC AACCAAACGCAGTGTCTCGTCCAC 622-795 
Satl1 ACCTGCTGAGCCTGAAGATTGC TGTCCCCAAAACCATCCCTG 1743-1867 
Serpina7 TGTCTTGGTATTTGGGCTTCAGG GAGTGGCATTTTGTTGGGGC 24-124 
Slc25a5 GCCTGACTTCCTATCCTTTTGACAC AAGCCTTGCTCCCTTCATCG 754-888 
Stard8 TTGTTAGGTCTTGTCCCCAGCC CACCCTTTTCTTTCCTCCTCAGAG 570-714 
Sytl4 TCGGCGACTGAAGAATGAGC CACACAAGTGCTGCTTTTGGG 293-428 
Tceal8 GCAAAAGTCTTGTGACGAGAACG ATGGCTCCCTTCAGTTTCCTCC 174-321 
Tmsb4x TGGCGAATCGTAATGAGGCG TGATGTGAAAGGGGCAGCAC 351-500 
Ubl4 TTCAGTGTAGCAGATGCCAGCAGG CCCTTTTTCCATAGCCTCAGTCAC 383-526 
Uty AGATAGCCTCTGCCGCTTTCTC GCCGCCATTTTCTTTTCCTC 251-351 
Wdr40b CCTTCAGCAACAAAAACCAGGAG TTCTCACGGCAATAGGGCAG 1153-1273 
Xlr3a GGCTTTCTTTGACATTCTGCTCTG CATCTTTCTTACTCGGGAGGTTTG 1074-1207 
Xlr3b ATCTTCTCCTGTCTTCCTCCTGTTC AAAGCCTGCCATCTCTACCTGAG 843-976 
Y-linked    
Uty AGATAGCCTCTGCCGCTTTCTC GCCGCCATTTTCTTTTCCTC 251-351 
Other    
Acot10 AAATCACAGAAAGTCCTACCACCG TCAAAGTCCTCAAGAATCCTGCC 311-456 
Des AACATCTCTGAGGCTGAAGAATGG TCAATCTCGCAGGTGTAGGACTGG 933-1078 
Egr1 TAATAGCAGCAGCAGCACCAGC CAGAGCGATGTCAGAAAAGGACTC 562-703 
Hnf3b CACTGGGGACAAGGGAAATGAG TTAGGGACACAGACAGGTGAGACTG 1624-1737 
Hnf4a TTCTGCGAACTCCTTCTGGATG CGAGGGACGATGTAGTCATTGC 839-975 
Hspb1 ACAGTGAAGACCAAGGAAGGCG ACCTGGAGGGAGCGTGTATTTC 337-450 
Ifng AGCAAGGCGAAAAAGGATGC AATCTCTTCCCCACCCCGAATCAG 453-625 
Il1b GTGAAATGCCACCTTTTGACAGTG TGTTGATGTGCTGCTGCGAG 94-240 
Il6 TGGAGCCCACCAAGAACGATAG CACCAGCATCAGTCCCAAGAAG 109-208 
Saa1 TTTGTTCACGAGGCTTTCCAAG CCTTTGAGCAGCATCATAGTTCCC 103-228 
Tnfa GCAGGTTCTGTCCCTTTCACTCAC TTCTGGAAGCCCCCCATCTTTTGG 95-233 
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Table 2. Top 10 up- and downregulated liver genes in AB6F1 versus B6AF1 males at 9 months 
as determined by microarray (mean signal density shown at right). 
Symbol  Gene Fold  AB6F1 B6AF1 
Upregulated in AB6F1 males    
Sult2a2 sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 2 239.98 10823 45 
Kcnt2 Potassium channel, subfamily T, member 2 35.57 2367 67 
Sult3a1 sulfotransferase family 3A, member 1 21.61 769 36 
Cyp2b13 cytochrome P450, family 2, subfamily b, polypeptide 13 14.74 9501 645 
Cfd complement factor D (adipsin) 11.76 3807 324 
Lcn2 lipocalin 2 11.68 3823 327 
Thbs1 thrombospondin 1 8.51 403 47 
Ly6d lymphocyte antigen 6 complex, locus D 8.24 610 74 
Saa2 serum amyloid A 2 8.18 4562 558 
Orm2 orosomucoid 2 8.02 7225 901 
Downregulated in AB6F1 males    
Slco1a1 solute carrier organic anion transporter family, member 1a1 -95.73 59 5682 
Hsd3b5 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 5 -62.08 37 2272 
Atp10a ATPase, class V, type 10A -14.30 4 55 
Usp3 ubiquitin specific peptidase 3 -9.53 10 98 
Clec2h C-type lectin domain family 2, member h -7.85 50 389 
Serpine2 serine (or cysteine) peptidase inhibitor, clade E, member 2 -7.57 121 915 
Evi5 Ecotropic viral integration site 5 -7.28 10 74 
Susd4 sushi domain containing 4 -6.05 166 1003 
Elovl3 elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3 -5.58 2752 15358 
Satl1 spermidine/spermine N1-acetyl transferase-like 1 -5.18 11 59 
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Table 3. Comparison of BW (g ± standard error of mean) and serum insulin (ng/dL) in A/J, 
B6.AX, B6.AY, B6AF1 and AB6F1 female (F) and male (M) mice on LF versus HF diet. 
 
 A/J B6.AX B6.AY B6AF1 AB6F1 
F BW LF diet 23.0 ± 0.5 21.2 ± 0.7 21.0 ± 0.5 25.8 ± 1.2 26.9 ± 0.7 
F BW HF diet 31.7 ± 1.4 30.0 ± 1.5 30.8 ± 2.3 39.0 ± 1.4 40.4 ± 3.3 
F BW % incr. 38% 42% 47% 51% 51% 
      
M BW LF diet 29.6 ± 0.7 26.7 ± 1.2 31.0 ± 0.8 34.6 ± 0.9 34.4 ± 1.2 
M BW HF diet 37.4 ± 2.3 45.2 ± 1.1 46.9 ± 1.0 44.8 ± 0.9 46.8 ± 1.0 
M BW % incr. 26% 69% 51% 29% 36% 
      
F insulin LF diet 1.2 ± 0.3 1.2 ± 0.1 1.2 ± 0.1 1.2 ± 0.1 1.6 ± 0.4 
F insulin HF diet 1.9 ± 0.7 2.4 ± 0.3 1.9 ± 0.3 3.7 ± 0.6 5.8 ± 1.1 
F insulin % incr. 58% 200% 58% 308% 363% 
      
M insulin LF diet 2.4 ± 0.3 1.6 ± 0.2 2.3 ± 0.2 4.0 ± 0.9 4.1 ± 0.8 
M insulin HF diet 4.7 ± 0.3 9.6 ± 2.1 11.2 ± 2.2 6.8 ± 1.0 16.8 ± 1.3 
M insulin % incr. 196% 600% 487% 170% 410% 
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Figure Legends 
 
Figure 1. Clinical metabolic parameters in AB6F1 versus B6AF1 male mice. AB6F1 males 
developed early and progressive insulin resistance and hepatic steatosis (fatty liver). Although 
AB6F1 males also had moderately increased body mass compared with B6AF1 mice, neither 
morbid obesity nor hyperglycemia (not shown) were components of the phenotype. *P < 0.05 
compared with age-matched B6AF1 mice. 
 
Figure 2. Histopathologic and genomic comparison of AB6F1 versus B6AF1 males. (A) AB6F1 
males exhibited more severe fatty liver lesions than B6AF1 males at all time points; lipid-filled 
vacuoles were verified by Oil Red O staining of frozen sections; immunohistochemical 
demonstration of PKM2 in AB6F1 neoplastic hepatocytes but not B6AF1 normal tissue. (B) 
AB6F1 liver demonstrating focus of cellular alteration and dysplasia characterized by marked 
pleomorphism, intranuclear pseudoinclusions (arrow), and oval cell hyperplasia (arrowheads; 
left); HCC arising on a background of metabolic hepatopathy (right). (C) Survey of non-hepatic 
insulin resistance-associated histologic lesions in AB6F1 males including WAT degeneration 
with MØ proliferation forming F4/80+ crown-like rosettes, metaplasia of thoracic BAT to a 
WAT phenotype, focal skeletal muscle degeneration with fatty replacement, and pancreatic 
hyperplasia with occasional megaislets. (D) Microarray heat map demonstrating hierarchal 
clustering of AB6F1 versus B6AF1 males. (E) Histologic comparison of macrovesicular steatosis 
with WAT (top), and microvesicular steatosis with BAT (bottom), consistent with transcriptional 
alterations characteristic of adipogenic transition. Magnifications: (A) 100X except bottom row 
400X; (B) 400X (left), 40X (right); (C) 200X; (E) 400X. 
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Figure 3. Serum insulin and body weight comparison between A/J, B6.AX, B6.AY, B6AF1 and 
AB6F1 mice on HF diet. Note dissociation between BW and serum insulin levels in F1 mice 
compared with other groups. 
 
Figure 4. Primary hepatocyte isolation and culture. (A) Flow cytometry demonstrating <2% 
white blood cell (WBC) contamination of enriched hepatocyte population; ~25% of hepatocytes 
labeled with anti-CD95/Fas antibody. (B) MTT assay demonstrating strong trend (P=0.07) for 
increased viability of insulin-supplemented cells versus dexamethasone-alone after 4 days of 
culture. Photomicrographs demonstrate organization of hepatocytes into crude canaliculi, with 
increased clear (lipid) cytoplasmic vacuoles in insulin-supplemented cells; magnification 1000X. 
(C) qRT-PCR of insulin-supplemented primary hepatocytes (dark gray columns), especially on 
day 4 of culture, demonstrating increased expression of adipocyte-associated genes including 
vimentin, collagen 3α-1, fatty acid translocase (CD36), and pyruvate kinase M2 compared with 
non-supplemented cells (light gray columns); these genes also were upregulated in AB6F1 
versus B6AF1 male mice at 15 months of age (black columns).   
 
 
 




